EZH2 in cancer progression and potential application in cancer therapy: A friend or foe?

Ke Sin Yan, Chia Yuan Lin, Tan Wei Liao, Cheng Ming Peng, Shou Chun Lee, Yi Jui Liu, Wing P. Chan, Ruey Hwang Chou

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, catalyzes trimethylation of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic machinery. EZH2 functions as a double-facet molecule in regulation of gene expression via repression or activation mechanisms, depending on the different cellular contexts. EZH2 interacts with both histone and non-histone proteins to modulate diverse physiological functions including cancer progression and malignancy. In this review article, we focused on the updated information regarding microRNAs (miRNAs) and long non coding RNAs (lncRNAs) in regulation of EZH2, the oncogenic and tumor suppressive roles of EZH2 in cancer progression and malignancy, as well as current pre-clinical and clinical trials of EZH2 inhibitors.

Original languageEnglish
Article number1172
JournalInternational Journal of Molecular Sciences
Volume18
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

gene expression
Gene expression
progressions
Histones
therapy
cancer
Long Noncoding RNA
machinery
RNA
MicroRNAs
inhibitors
Machinery
Tumors
flat surfaces
Neoplasms
coding
tumors
Chemical activation
activation
proteins

Keywords

  • Cancer
  • Epigenetic regulation
  • EZH2
  • EZH2 inhibitors
  • lncRNAs
  • microRNAs

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Computer Science Applications
  • Spectroscopy
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Yan, K. S., Lin, C. Y., Liao, T. W., Peng, C. M., Lee, S. C., Liu, Y. J., ... Chou, R. H. (2017). EZH2 in cancer progression and potential application in cancer therapy: A friend or foe? International Journal of Molecular Sciences, 18(6), [1172]. https://doi.org/10.3390/ijms18061172

EZH2 in cancer progression and potential application in cancer therapy : A friend or foe? / Yan, Ke Sin; Lin, Chia Yuan; Liao, Tan Wei; Peng, Cheng Ming; Lee, Shou Chun; Liu, Yi Jui; Chan, Wing P.; Chou, Ruey Hwang.

In: International Journal of Molecular Sciences, Vol. 18, No. 6, 1172, 01.06.2017.

Research output: Contribution to journalReview article

Yan, Ke Sin ; Lin, Chia Yuan ; Liao, Tan Wei ; Peng, Cheng Ming ; Lee, Shou Chun ; Liu, Yi Jui ; Chan, Wing P. ; Chou, Ruey Hwang. / EZH2 in cancer progression and potential application in cancer therapy : A friend or foe?. In: International Journal of Molecular Sciences. 2017 ; Vol. 18, No. 6.
@article{6827bc61f17043c78d6357e2dc3fe227,
title = "EZH2 in cancer progression and potential application in cancer therapy: A friend or foe?",
abstract = "Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, catalyzes trimethylation of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic machinery. EZH2 functions as a double-facet molecule in regulation of gene expression via repression or activation mechanisms, depending on the different cellular contexts. EZH2 interacts with both histone and non-histone proteins to modulate diverse physiological functions including cancer progression and malignancy. In this review article, we focused on the updated information regarding microRNAs (miRNAs) and long non coding RNAs (lncRNAs) in regulation of EZH2, the oncogenic and tumor suppressive roles of EZH2 in cancer progression and malignancy, as well as current pre-clinical and clinical trials of EZH2 inhibitors.",
keywords = "Cancer, Epigenetic regulation, EZH2, EZH2 inhibitors, lncRNAs, microRNAs",
author = "Yan, {Ke Sin} and Lin, {Chia Yuan} and Liao, {Tan Wei} and Peng, {Cheng Ming} and Lee, {Shou Chun} and Liu, {Yi Jui} and Chan, {Wing P.} and Chou, {Ruey Hwang}",
year = "2017",
month = "6",
day = "1",
doi = "10.3390/ijms18061172",
language = "English",
volume = "18",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "6",

}

TY - JOUR

T1 - EZH2 in cancer progression and potential application in cancer therapy

T2 - A friend or foe?

AU - Yan, Ke Sin

AU - Lin, Chia Yuan

AU - Liao, Tan Wei

AU - Peng, Cheng Ming

AU - Lee, Shou Chun

AU - Liu, Yi Jui

AU - Chan, Wing P.

AU - Chou, Ruey Hwang

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, catalyzes trimethylation of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic machinery. EZH2 functions as a double-facet molecule in regulation of gene expression via repression or activation mechanisms, depending on the different cellular contexts. EZH2 interacts with both histone and non-histone proteins to modulate diverse physiological functions including cancer progression and malignancy. In this review article, we focused on the updated information regarding microRNAs (miRNAs) and long non coding RNAs (lncRNAs) in regulation of EZH2, the oncogenic and tumor suppressive roles of EZH2 in cancer progression and malignancy, as well as current pre-clinical and clinical trials of EZH2 inhibitors.

AB - Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, catalyzes trimethylation of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic machinery. EZH2 functions as a double-facet molecule in regulation of gene expression via repression or activation mechanisms, depending on the different cellular contexts. EZH2 interacts with both histone and non-histone proteins to modulate diverse physiological functions including cancer progression and malignancy. In this review article, we focused on the updated information regarding microRNAs (miRNAs) and long non coding RNAs (lncRNAs) in regulation of EZH2, the oncogenic and tumor suppressive roles of EZH2 in cancer progression and malignancy, as well as current pre-clinical and clinical trials of EZH2 inhibitors.

KW - Cancer

KW - Epigenetic regulation

KW - EZH2

KW - EZH2 inhibitors

KW - lncRNAs

KW - microRNAs

UR - http://www.scopus.com/inward/record.url?scp=85020180686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020180686&partnerID=8YFLogxK

U2 - 10.3390/ijms18061172

DO - 10.3390/ijms18061172

M3 - Review article

AN - SCOPUS:85020180686

VL - 18

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 6

M1 - 1172

ER -